Committee Recommends Sanofi’s Multaq For Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite issues with ATHENA and ANDROMEDA, committee recommends approval of Multaq, but not with the mortality claim Sanofi-Aventis hoped for.
You may also be interested in...
FDA Approves Multaq With REMS, Without Mortality Claim
FDA approves Sanofi-Aventis’ atrial fibrillation drug Multaq with a Risk Evaluation and Mitigation Strategy to ensure the drug is used only in patients whose hearts have returned to normal rhythm.
FDA Approves Multaq With REMS, Without Mortality Claim
FDA approves Sanofi-Aventis’ atrial fibrillation drug Multaq with a Risk Evaluation and Mitigation Strategy to ensure the drug is used only in patients whose hearts have returned to normal rhythm.
Merck Pumps Pipeline With $800M Cardiome Deal
FDA-delayed vernakalant for atrial fibrillation nets handsome pact, as more-lucrative oral form awaits Phase III trials.